<DOC>
	<DOCNO>NCT01659255</DOCNO>
	<brief_summary>This open-label , multi-center , phase I dose-escalation study investigate safety tolerability ONO/GS-4059 give monotherapy patient relapsed/refractory NHL CLL .</brief_summary>
	<brief_title>Phase I Study ONO-4059 ( ONO/GS-4059 ) Given Monotherapy Patients With Relapsed/Refractory NHL CLL</brief_title>
	<detailed_description>An open-label , multi-center , non-randomized phase I dose-escalation study investigate safety tolerability ONO/GS-4059 give monotherapy patient relapsed/refractory Non-Hodgkin 's lymphoma ( NHL ) relapsed/refractory chronic lymphocytic leukemia ( CLL ) . Non-Hodgkin 's lymphoma heterogeneous group malignancy vary clinical biological feature . Leukemia type cancer blood bone marrow characterize abnormal increase immature white blood cell . Chronic lymphocytic leukemia ( CLL ) common type adult leukemia affect blood bone marrow .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>1 . Males female confirm diagnosis document history relapse refractory malignant disease ( Bcell lymphoma and/or CLL ) therapy curative high priority exist treatment Btk inhibitor may deem appropriate . 2 . Age ≥18 year . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . 1 . Central nervous system ( CNS ) lymphoma . 2 . Women pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>